The effectiveness of treatment in non-small-cell lung cancer (NSCLC) depends on the accurate determination of the genomic status of the tumour. For this reason, molecular analyses to detect tumour genomic aberrations have become standard of care in patients with advanced disease, and now also in patients with early disease.
Please join us for this unique opportunity to take a deep dive into the Lung Cancer Molecular Diagnostic Pathway, with a specific focus on tumour molecular testing. We will cover how to ensure optimal tissue sampling and the tissue requirements for molecular testing as well as discussing the successes, challenges and applications of ctDNA in lung cancer diagnosis.
Agenda/find out more here
The day will include a unique opportunity to hear from several leading clinical scientists from two London Genomic Laboratory Hubs. They will discuss the key assays used in the genomic laboratory, and will provide a useful guide to the interpretation of an NGS report for the clinician, as well as offering an exclusive insider view on the benefits and challenges of the recent changes to genomic testing services across the UK.
Finally the information learnt will be brought together in a number of illustrated case presentations and discussions led by two lung cancer medical oncologists.
Who should attend?
Junior to intermediate level clinicians as well as consultants in oncology and respiratory medicine. Other healthcare professionals within the lung cancer multidisciplinary team.
Book your place here